Nat Milton

Nat has a background in Neurochemistry, having gained a PhD in Neuroendocrinology, (King’s College London) and an international reputation in the Alzheimer’s drug discovery research field. He has led the Amyloid-Binding Peptides Research Group since 1996, which discovered Catalase binding to Amyloid fibrils associated with Alzheimer’s disease, Creutzfeldt-Jakob disease, Diabetes, Familial British Dementia, Familial Danish Dementia and Parkinson’s disease. He was the first to demonstrate Cannabinoid neuroprotection against the Alzheimer’s amyloid-beta and has developed anti-amyloid peptide drugs from derivatives of Kisspeptin.

Nat is a Fellow of the Institute of Biomedical Science. He has research and development experience and has used this to take inventions through the patent process to grant in Europe and also to found a Biotechnology company.

He has teaching experience in Biomedical Sciences at both undergraduate and postgraduate level. With a PGCert in Learning & Teaching in Higher Education (Roehampton University) Nat is also a Fellow of the Higher Education Academy.

Qualifications:

BSc in Biological Sciences
PhD in Neuroendocrinology
PGCert in Learning and Teaching in Higher Education

Nat is a research-driven individual with experience of using molecular and cellular techniques in the areas of Alzheimer’s drug discovery and amyloid peptide research. He has led his own research teams in University Departments. He has published extensively, raised funding, supervised PhD students and been heavily involved in entrepreneurial activities. He has previously been an active member of the Biomedical Sciences teaching teams at the Universities of Roehampton and Westminster. He was a London Technology Network Business Fellow and also a Company Director for NeuroDelta Ltd. He gained management experience as a Course Leader, Senior Tutor and company director.

Nat’s current research is focused on neuroprotective strategies against amyloid peptides. He is currently extending the work on catalase neuroprotection and also looking at the neuroprotective properties of opioid peptides. He is also using Bioinformatic screening to identify novel amyloid binding peptides.